文献速递神经眼科眼外伤

外伤性视神经病变治疗试验2(TONTT-2):评估不同剂量促红细胞生成素疗效的多中心、随机、双盲临床试验

Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2): evaluating the efficacy of different doses of erythropoietin - a multicentre, randomised, double-blind clinical trial.
PubMed 文献 · Br J Ophthalmol · 2025-03-20

这项多中心、随机、双盲、剂量探索试验比较了三种按体重调整的静脉促红细胞生成素(EPO)剂量(900 IU/kg、1800 IU/kg、3600 IU/kg)治疗间接性外伤性视神经病变(TON)的疗效与安全性。共95例患者随机分组,93例完成随访。结果显示三组最佳矫正视力(BCVA)和相对性传入性瞳孔缺陷(RAPD)均显著改善且组间无显著差异,仅3600 IU/kg组色觉显著改善(p=0.005),但最终色觉组间无显著差异(p=0.49)。结论认为增加EPO剂量未带来更好的BCVA、色觉和RAPD改善。

要点

  • 三组BCVA和RAPD均显著改善,但组间无显著差异。
  • 仅3600 IU/kg组色觉显著改善(p=0.005),最终色觉组间无显著差异(p=0.49)。
  • 无光感、年龄较大、创伤-治疗间隔较长和后眶骨折与视力恢复较差显著相关。

核心结论

  • 增加TON患者的EPO剂量未导致BCVA、色觉和RAPD改善更优。

研究设计与样本

  • 多中心、随机、平行组、双盲、剂量探索试验,纳入年龄≥7岁且确诊间接性TON≤3周的患者。
  • 试验含3天治疗期和3个月随访期,患者按1:1:1随机分配至EPO 900 IU/kg(300 IU/kg/天)、1800 IU/kg(600 IU/kg/天)或3600 IU/kg(600 IU/kg/天,就诊时给药后1个月再给药)组。
  • 118例符合条件患者中95例随机分组,93例(每组31例)完成随访。

主要发现

  • 三组基线BCVA(p=0.66)、色觉(p=0.25)和RAPD(p=0.79)无差异。
  • 三组BCVA和RAPD均显著改善,组间无显著差异。
  • 仅3600 IU/kg EPO组色觉显著改善(p=0.005),但最终色觉组间无显著差异(p=0.49)。
  • 初始无光感(OR=7.79,95%CI:2.98至20.36,p<0.001)、年龄较大(OR=4.76,95%CI:1.92至11.76,p<0.001)、创伤-治疗间隔较长(OR=2.72,95%CI:1.16至6.33,p=0.02)和后眶骨折(OR=2.63,95%CI:1.13至6.13,p=0.02)导致视力恢复显著更差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim is to compare the efficacy and safety of three different weight-adjusted intravenous erythropoietin (EPO) doses in patients with indirect traumatic optic neuropathy (TON). METHODS: This study is a multicentre, randomised, parallel-group, double-blind, dose-finding trial on patients aged ≥7 years with a confirmed diagnosis of indirect TON in ≤3 weeks. The trial had a 3-day treatment period and a 3-month follow-up period. Patients were randomly allocated (1:1:1) to receive EPO at doses of 900 IU/kg (300 IU/kg/day), 1800 IU/kg (600 IU/kg/day) or 3600 IU/kg (600 IU/kg/day on presentation and then 1 month later) EPO. The changes in the best-corrected visual acuity (BCVA), colour vision and relative afferent pupillary defect (RAPD) were assessed. RESULTS: Out of 118 eligible patients, 95 were randomised and 93 (31 in each group) completed the follow-ups. Three groups were not different regarding baseline BCVA (p=0.66), colour vision (p=0.25) and RAPD (p=0.79). All three groups showed a significant improvement of BCVA and RAPD with no significant differences among the groups. Colour vision showed a significant improvement only in the group with 3600 IU/kg EPO (p=0.005), even though final colour vision was not significantly different between the groups (p=0.49). Initial vision of no light perception (OR=7.79 (95% CI: 2.98 to 20.36), p<0.001), older age (OR=4.76 (95% CI: 1.92 to 11.76), p<0.001), longer trauma-treatment interval (OR=2.72, 95% CI: 1.16 to 6.33, p=0.02) and posterior orbital fractures (OR=2.63 (95% CI: 1.13 to 6.13), p=0.02) led to a significantly worse visual recovery. CONCLUSION: Increasing dose of EPO in patients with TON did not result in a better BCVA, colour vision and RAPD improvement. TRIAL REGISTRATION NUMBER: NCT03308448.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Abdolalizadeh P, Kashkouli MB, Ghazizadeh M, et al. Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2): evaluating the efficacy of different doses of erythropoietin - a multicentre, randomised, double-blind clinical trial. Br J Ophthalmol. 2025. PMID: 39461733. doi:10.1136/bjo-2024-325828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。